Search

everythinglearnresearchcommunity

for

Search:↓

Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.

Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.

Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.

Pembrolizumab can cause serious liver issues, requiring close monitoring and early treatment.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

UDCA reduces inflammation and joint damage in rheumatoid arthritis.

Intensive immunosuppression can reduce relapse rates in multiple sclerosis patients, despite some side effects.

Tocilizumab therapy may cause skin and hair conditions like halo naevi, vitiligo, and alopecia areata.

Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.

New vitamin D3 forms need the vitamin D receptor to reduce fibrosis in human cells.

Wedelolactone may help prevent bone damage in breast cancer by blocking certain cell signals.

The consensus provides guidelines for safely stopping danazol in hereditary angioedema treatment.

Budesonide is not effective for maintaining remission in Crohn's disease beyond three months.

Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.

Bevacizumab may worsen hypothyroidism, so thyroid function should be monitored during treatment.

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.

Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.

The treatment showed high response rates and was well-tolerated, potentially extending patient survival.

A woman with severe angioedema improved significantly after treatment with rituximab.

Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

Adalimumab improved folliculitis decalvans in most patients.

Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.

Lokivetmab reduced itching in a dog with skin lymphoma.

Two new IRAK4-inhibitors effectively reduced skin inflammation and immune response markers in healthy volunteers.

Anti-CD19 therapy may help treat SLE and NMOSD.

Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.